Immuneering Corp Stock Today
| IMRX Stock | USD 2.13 0.08 3.90% |
Performance11 of 100
| Odds Of DistressLess than 26
|
Immuneering Corp is trading at 2.13 as of the 28th of November 2024; that is 3.90% increase since the beginning of the trading day. The stock's open price was 2.05. Immuneering Corp has about a 26 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Immuneering Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. Immuneering Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 31.05 M outstanding shares of which 2.05 M shares are currently shorted by private and institutional investors with about 1.19 trading days to cover. More on Immuneering Corp
Moving against Immuneering Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immuneering Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CoFounder | Dr MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmuneering Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immuneering Corp's financial leverage. It provides some insight into what part of Immuneering Corp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immuneering Corp (IMRX) is traded on NASDAQ Exchange in USA. It is located in 245 Main Street, Cambridge, MA, United States, 02142 and employs 66 people. Immuneering Corp is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.65 M. Immuneering Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 31.05 M outstanding shares of which 2.05 M shares are currently shorted by private and institutional investors with about 1.19 trading days to cover.
Immuneering Corp currently holds about 128.1 M in cash with (48.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Immuneering Corp Probability Of Bankruptcy
Ownership AllocationImmuneering Corp has a total of 31.05 Million outstanding shares. Immuneering Corp secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immuneering Ownership Details
Immuneering Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 92.1 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 88.8 K | |
| Manufacturers Life Insurance Co | 2024-09-30 | 82.6 K | |
| Exchange Traded Concepts, Llc | 2024-06-30 | 74.9 K | |
| Jane Street Group Llc | 2024-06-30 | 74.8 K | |
| State Street Corp | 2024-06-30 | 69.2 K | |
| Tidemark Llc | 2024-09-30 | 51.9 K | |
| Hightower Advisors, Llc | 2024-06-30 | 44 K | |
| Ci Private Wealth Llc | 2024-06-30 | 43.4 K | |
| Vanguard Group Inc | 2024-09-30 | 1.1 M | |
| Millennium Management Llc | 2024-06-30 | 953.2 K |
Immuneering Corp Historical Income Statement
Immuneering Stock Against Markets
Immuneering Corp Corporate Management
| Praveen Nair | Head VP | Profile | |
| Mallory CPA | Principal Fin | Profile | |
| Mohamedi MBA | Head Devel | Profile | |
| Leah Neufeld | Chief Officer | Profile | |
| Brett Hall | Chief Officer | Profile | |
| Harold Brakewood | Chief Officer | Profile |
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.